The presence of DNMT3A mutations in nearly all bone marrow cells of MDS patients independent of blast count, has led to the hypothesis that this is an early genetic event in the disease process and may result in a clonal advantage of the mutated cells (99). This evidence concerns the gene DNMT3A and myelodysplastic syndrome.